1. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. (January 2022) Authors: Vermeire, Severine; Lakatos, Peter L; Ritter, Timothy; Hanauer, Stephen; Bressler, Brian; Khanna, Reena; Isaacs, Kim; Shah, Saumin; Kadva, Alysha; Tyrrell, Helen; Oh, Young S; Tole, Swati; Chai, Akiko; Pulley, Jennifer; Eden, Christopher; Zhang, Wenhui; Feagan, Brian G; Abraham, Philip; Acir Crip... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Vedolizumab Resulted in Resolution of Anti‐tumor Necrosis Factor Psoriasis and Sustained Clinical and Endoscopic Remission of Crohn's Colitis: 662. (October 2015) Authors: White, Betty; Holderman, William Journal: American journal of gastroenterology Issue: Volume 110(2015)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S3298 The Impact of COVID-19 on Gastroenterology Community Practice: The Results of a Multi-Practice, Multi-State Survey. (October 2020) Authors: Fourment, Christopher; Holderman, William; Wohlman, Robert A.; Leavitt, James; Sugar, Jason; Aycock, Richard; Weinstein, Michael; Ketover, Scott R.; Cappa, Joseph; Nestler, Jeffry; Hennessy, Bruce; Ritter, Timothy E.; Shaffer, Robert; Hogan, Reed B. Journal: American journal of gastroenterology Issue: Volume 115:Supplement(2020)ACG Annual Meeting Abstracts 1 Page Start: S1719 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S1254 Impact of COVID-19 on a Large, Vertically Integrated Gastroenterology Community Practice. (October 2020) Authors: Holderman, William; Fourment, Christopher; Wohlman, Robert A.; Fruge, Cindy; Ortega, Matt Journal: American journal of gastroenterology Issue: Volume 115:Supplement(2020)ACG Annual Meeting Abstracts 1 Page Start: S631 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P-230 YI Vedolizumab Resulted in Resolution of Anti-Tumor Necrosis Factor Psoriasis and Sustained Clinical and Endoscopic Remission of Crohn's Colitis. (March 2016) Authors: White, Betty; Holderman, William Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P-230 YI Vedolizumab Resulted in Resolution of Anti-Tumor Necrosis Factor Psoriasis and Sustained Clinical and Endoscopic Remission of Crohn's Colitis. (March 2016) Authors: White, Betty; Holderman, William Journal: Inflammatory bowel diseases Issue: Volume 22(2016:Mar.)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. (April 2023) Authors: Feagan, Brian G; Sands, Bruce E; Sandborn, William J; Germinaro, Matthew; Vetter, Marion; Shao, Jie; Sheng, Shihong; Johanns, Jewel; Panés, Julián; Tkachev, Alexander; Kalimullina, Dilara; Petryka, Robert; Osipenko, Marina; Tsarynna, Nataliia; Bilianskyi, Leonid; Kleczkowski, Dariusz; Yurkiv, And... Journal: Lancet gastroenterology and hepatology Issue: Volume 8:Number 4(2023) Page Start: 307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗